全文获取类型
收费全文 | 33009篇 |
免费 | 1809篇 |
国内免费 | 147篇 |
专业分类
耳鼻咽喉 | 350篇 |
儿科学 | 733篇 |
妇产科学 | 581篇 |
基础医学 | 6262篇 |
口腔科学 | 743篇 |
临床医学 | 2616篇 |
内科学 | 6263篇 |
皮肤病学 | 854篇 |
神经病学 | 3404篇 |
特种医学 | 1424篇 |
外科学 | 4580篇 |
综合类 | 151篇 |
一般理论 | 14篇 |
预防医学 | 1658篇 |
眼科学 | 721篇 |
药学 | 2315篇 |
中国医学 | 21篇 |
肿瘤学 | 2275篇 |
出版年
2022年 | 161篇 |
2021年 | 345篇 |
2020年 | 293篇 |
2019年 | 488篇 |
2018年 | 570篇 |
2017年 | 437篇 |
2016年 | 564篇 |
2015年 | 651篇 |
2014年 | 781篇 |
2013年 | 1170篇 |
2012年 | 1626篇 |
2011年 | 1748篇 |
2010年 | 1176篇 |
2009年 | 1127篇 |
2008年 | 1883篇 |
2007年 | 1920篇 |
2006年 | 1791篇 |
2005年 | 1916篇 |
2004年 | 1793篇 |
2003年 | 1761篇 |
2002年 | 1842篇 |
2001年 | 341篇 |
2000年 | 266篇 |
1999年 | 386篇 |
1998年 | 502篇 |
1997年 | 412篇 |
1996年 | 367篇 |
1995年 | 337篇 |
1994年 | 289篇 |
1993年 | 258篇 |
1992年 | 209篇 |
1991年 | 204篇 |
1990年 | 170篇 |
1989年 | 161篇 |
1988年 | 169篇 |
1985年 | 157篇 |
1984年 | 181篇 |
1983年 | 161篇 |
1982年 | 198篇 |
1981年 | 169篇 |
1978年 | 135篇 |
1933年 | 170篇 |
1932年 | 180篇 |
1931年 | 167篇 |
1930年 | 169篇 |
1929年 | 147篇 |
1928年 | 163篇 |
1927年 | 144篇 |
1926年 | 158篇 |
1925年 | 139篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
981.
Stanley C. Jordan Klaus Kucher Morten Bagger Hans‐Ulrich Hockey Kristina Wagner Noriko Ammerman Ashley Vo 《American journal of transplantation》2020,20(9):2581-2588
Awareness of drug‐drug interactions is critical in organ transplant recipient management. However, biologic agents interfering with monoclonal antibodies is not widely considered. We report the effect of high‐dose intravenous immunoglobulin (IVIg) on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the human anti‐C5 monoclonal antibody tesidolumab (LFG316) in end‐stage renal disease patients awaiting kidney transplant. In this single‐center, phase 1, open‐label, parallel‐group study, 8 patients were assigned to receive either single‐dose tesidolumab + IVIg or tesidolumab alone, with 56‐day follow‐up. Within‐group PK parameters were consistent. Mean tesidolumab exposure decreased 34%, clearance increased 63%, and half‐life decreased 41% comparing tesidolumab + IVIg to tesidolumab alone. IVIg influence on tesidolumab elimination was most evident in the first 3 weeks. Complete suppression of both total and alternative complement activities was maintained for 4 weeks in the tesidolumab alone group and for 2 weeks in the tesidolumab + IVIg group. Tesidolumab was well tolerated. IVIg infused before tesidolumab affected tesidolumab PK and PD, resulting in a shortened period of full complement activity inhibition. These findings suggest a clinically relevant impact of IVIg on monoclonal antibody clearance and indirectly hint at an IVIg mechanism of action in treating autoimmune diseases and allosensitization by accelerating pathogenic IgG antibody degradation. Trial registration number: NCT02878616. 相似文献
982.
983.
Rabea Hein Hendrik J. Sake Claudia Pokoyski Joachim Hundrieser Antje Brinkmann Wiebke Baars Monika Nowak‐Imialek Andrea Lucas‐Hahn Constanca Figueiredo Hans‐Joachim Schuberth Heiner Niemann Bjrn Petersen Reinhard Schwinzer 《American journal of transplantation》2020,20(4):988-998
Porcine xenografts lacking swine leukocyte antigen (SLA) class I are thought to be protected from human T cell responses. We have previously shown that SLA class I deficiency can be achieved in pigs by CRISPR/Cas9‐mediated deletion of β2‐microglobulin (B2M). Here, we characterized another line of genetically modified pigs in which targeting of the B2M locus did not result in complete absence of B2M and SLA class I but rather in significantly reduced expression levels of both molecules. Residual SLA class I was functionally inert, because no proper differentiation of the CD8+ T cell subset was observed in B2Mlow pigs. Cells from B2Mlow pigs were less capable in triggering proliferation of human peripheral blood mononuclear cells in vitro, which was mainly due to the nonresponsiveness of CD8+ T cells. Nevertheless, cytotoxic effector cells developing from unaffected cell populations (eg, CD4+ T cells, natural killer cells) lysed targets from both SLA class I+ wildtype and SLA class Ilow pigs with similar efficiency. These data indicate that the absence of SLA class I is an effective approach to prevent the activation of human CD8+ T cells during the induction phase of an anti‐xenograft response. However, cytotoxic activity of cells during the effector phase cannot be controlled by this approach. 相似文献
984.
Xingyu Wang Roumen Parapanov Anne Debonneville Yabo Wang Etienne Abdelnour‐Berchtold Michel Gonzalez Fabrizio Gronchi Jean‐Yannis Perentes Hans‐Beat Ris Philippe Eckert Lise Piquilloud Jrme Lugrin Igor Letovanec Thorsten Krueger Lucas Liaudet 《American journal of transplantation》2020,20(4):967-976
Ex vivo lung perfusion (EVLP) with pharmacological reconditioning may increase donor lung utilization for transplantation (LTx). 3‐Aminobenzamide (3‐AB), an inhibitor of poly(ADP‐ribose) polymerase (PARP), reduces ex vivo lung injury in rat lungs damaged by warm ischemia (WI). Here we determined the effects of 3‐AB reconditioning on graft outcome after LTx. Three groups of donor lungs were studied: Control (Ctrl): 1 hour WI + 3 hours cold ischemia (CI) + LTx; EVLP: 1 hour WI + 3 hours EVLP + LTx; EVLP + 3‐AB: 1 hour WI + 3 hours EVLP + 3‐AB (1 mg.mL?1) + LTx. Two hours after LTx, we determined lung graft compliance, edema, histology, neutrophil counts in bronchoalveolar lavage (BAL), mRNA levels of adhesion molecules within the graft, as well as concentrations of interleukin‐6 and 10 (IL‐6, IL‐10) in BAL and plasma. 3‐AB reconditioning during EVLP improved compliance and reduced lung edema, neutrophil infiltration, and the expression of adhesion molecules within the transplanted lungs. 3‐AB also attenuated the IL‐6/IL‐10 ratio in BAL and plasma, supporting an improved balance between pro‐ and anti‐inflammatory mediators. Thus, 3‐AB reconditioning during EVLP of rat lung grafts damaged by WI markedly reduces inflammation, edema, and physiological deterioration after LTx, supporting the use of PARP inhibitors for the rehabilitation of damaged lungs during EVLP. 相似文献
985.
986.
Elizabeth Zaniewski Cam H Dao Ostinelli Frdrique Chammartin Nicola Maxwell Mary‐Ann Davies Jonathan Euvrard Janneke van Dijk Samuel Bosomprah Sam Phiri Frank Tanser Nosisa Sipambo Josephine Muhairwe Geoffrey Fatti Hans Prozesky Robin Wood Nathan Ford Matthew P Fox Matthias Egger 《Journal of the International AIDS Society》2020,23(7)
987.
988.
Sarah Bonk MD Martina Kluth PhD Kristina Jansen MD Claudia Hube-Magg PhD Georgia Makrypidi-Fraune PhD Doris Höflmayer MD Sören Weidemann MD Katharina Möller MD Ria Uhlig MD Franziska Büscheck MD Andreas M. Luebke MD Eike Burandt MD Till S. Clauditz MD Stefan Steurer MD Thorsten Schlomm MD Hartwig Huland MD Hans Heinzer MD Guido Sauter MD Ronald Simon PhD David Dum MD 《The Prostate》2020,80(13):1097-1107
989.
990.